Clinical Trial

Sugammadex Vs Neostigmine in Reversing Neuromuscular Blocks in Outpatient ERCP. A Randomized, Double-Blinded Trial

Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The investigators propose a single-center, assessor-Blinded, parallel group randomized trial to compare the efficacy of reversal of rocuronium induced neuromuscular blockade by sugammadex versus neostigmine in patients undergoing Endoscopic retrograde cholangiopancreatography at Cleveland Clinic Fairview Hospital.
Protocol Amendment History 8 amendments
This ClinicalTrials.gov record has been amended 8 times since 2023-11-13; most recent amendment 2025-12-09.
Status change: Not Yet Recruiting → Recruiting 2024-06-28
Trial Details
NCT Number NCT06136585
Lead Sponsor The Cleveland Clinic
Collaborators: Merck Sharp & Dohme LLC
Conditions Neuromuscular Blocks
Enrollment 80 participants
Start Date 2024-06-01
Primary Completion 2026-10-31 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-12-15